| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Streamex Corp.$0.86
-0.02 (-2.32%)
Market Cap
103.58 M
EPS
-9.85
P/E Ratio
-0.11 $
Value Trade
1.51 M
SEC Financials
Q1 2026Dilution Risk
Operating CF
-10.18 M
Total Assets
173.32 M
Total Liabilities
13.97 M
Equity
158.99 M
D/E Ratio
12,345
-7.85 %
Week
24.21 %
1 Month
-16.31 %
3 Month
765.25 %
6 Month
-99.03 %
5 Year
-99.73 %
All Time
Cash Data
Cash Position
6.86 M
Monthly Burn
3.39 M
Runway
0.9 mo
Burn Trend
SEC Filing
May 14, 2026
Overview
Volume
1.64 M
52 Week Range
0.49 - 14.11
% held by Insiders
35.46 %
% held by Institutions
24 %
Enterprise Value
111.72 M
Total Shares
91.48 M
Short %
12.78 %
Float Shares
54.16 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in STEX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Streamex Corp. (STEX) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
STEX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
STEX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
STEX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
STEX Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
STEX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
STEXStreamex Corp. and Orca Announce Launch of 24/7 Decentralized Secondary Liquidity Infrastructure for Tokenized Securities; GLDY the Inaugural Asset
Streamex Corp has launched a 24/7 decentralized secondary liquidity infrastructure for trading tokenized securities, developed in partnership with Orca. The GLDY token, which is a gold-backed, yield-bearing security, is the first asset to utilize this new platform. This initiative addresses the lack of reliable trading venues for tokenized assets and aims to foster institutional adoption. However, investors should note that GLDY tokens have restrictions on resale and that the trading volume in the secondary market is uncertain.
Read more →STEXStreamex Corp. Appoints Former Microsoft and PayPal Lead Product Designer Kori Handy as Vice President of Product and Design
Streamex Corp. has appointed Kori Handy as the new Vice President of Product and Design. Handy, who has a robust background in scaling fintech platforms, will oversee the evolution of the GLDY user experience as the company shifts from infrastructure development to expansion into mass-market financial products. He brings nearly two decades of experience from notable companies such as Microsoft and PayPal, signaling a strategic move for Streamex at a pivotal moment in its growth. His leadership is expected to enhance product strategy and user experience across the Streamex ecosystem.
Read more →STEXStreamex Corp. Clarifies and Refutes Inaccurate Claims Regarding Lock-Up Agreements; Co-Founders Morgan Lekstrom & Henry McPhie Enter into Voluntary 1 Year Lock-Up Agreements Winter Park, FL
Streamex Corp. has clarified and denied inaccurate reports regarding the expiration of lock-up agreements related to its shares. The company confirmed that its co-founders, Morgan Lekstrom and Henry McPhie, have voluntarily entered into one-year lock-up agreements to reflect their commitment to the company. Furthermore, the firm emphasized its strong capital position and upcoming catalysts in its business strategy. This clarification follows misleading information circulated by third parties.
Read more →STEXStreamex Corp. Appoints Christine Plummer, Former Global Controller at Coinbase and Managing Director at Morgan Stanley, as Chief Financial Officer
Streamex Corp. has appointed Christine Plummer, who previously served as the Global Controller at Coinbase and held senior roles at Morgan Stanley, as its new Chief Financial Officer. Plummer will oversee the company's global finance functions as it advances its tokenization initiatives within the financial infrastructure space. The company, focused on the tokenization of commodity assets, is optimistic about leveraging her extensive experience in traditional finance and digital asset frameworks to foster growth and support the launch of new tokenized products.
Read more →STEXStreamex Corp. Appoints Shawn Matthews, Former CEO of Cantor Fitzgerald & Co. & Founder and CIO of Hondius Capital Management, to Board of Directors
Streamex Corp. has appointed Shawn Matthews, former CEO of Cantor Fitzgerald & Co., to its Board of Directors. This move is anticipated to leverage Matthews' extensive experience in capital markets to support the company's growth and governance. Matthews, who has over three decades in global investing, expressed his excitement about joining Streamex at a pivotal time for financial markets, highlighting the company's focus on bridging traditional finance and digital assets.
Read more →STEXStreamex Corp. (NASDAQ: STEX) Appoints Morgan Lekstrom as Executive Chairman, & Announces Completed Repayment of Convertible Debenture and Cancellation of SEPA Winter Park, FL
Streamex Corp. has announced the appointment of its co-founder, Morgan Lekstrom, as Executive Chairman. This leadership change comes alongside the completion of the repayment of Secured Convertible Debentures, removing debt from the company’s balance sheet. The previously entered into Standby Equity Purchase Agreement has also been cancelled, providing the company with more financial flexibility. Streamex aims to enhance its position in the tokenization and digital asset infrastructure sector as it prepares for growth initiatives and the GLDY launch in 2026.
Read more →STEXStreamex Corp. (NASDAQ: STEX) Appoints Anthony Marciano, Clinical Professor of Finance at NYU Stern to Board of Directors Winter Park, FL
Streamex Corp. has appointed Anthony Marciano, a Clinical Professor of Finance at NYU Stern, to its Board of Directors. His experience in institutional finance and corporate governance is expected to provide significant value as the company aims for continued growth. CEO Henry McPhie praised Marciano's deep expertise and his potential contributions to the company's strategic initiatives. This appointment aligns with Streamex's focus on tokenization and digital asset infrastructure.
Read more →STEXStreamex Corp. (NASDAQ: STEX) Announces Issuance of Prepayment Notice for Previously Announced Convertible Debenture Financing & Notice of Termination for Standby Equity Purchase Agreement
Streamex Corp. has issued a prepayment notice for its Secured Convertible Debentures, intending to repay the total principal amount of $50 million along with a 10% prepayment premium. Additionally, the company has terminated its Standby Equity Purchase Agreement with Yorkville, marking a strategic move to improve its balance sheet. The CEO highlighted this as a preparation for an important year ahead, with anticipated product launches and a solid equity position. However, the company acknowledges various risks associated with meeting financing conditions and regulatory approvals.
Read more →STEXStreamex Corp. (NASDAQ: STEX) Announces Proposed Public Offering Winter Park, FL
Streamex Corp. (NASDAQ: STEX) announced a proposed public offering of common stock aimed at raising capital. The offering's completion is subject to market conditions, with no guarantees regarding its timing or size. Net proceeds will be used to repay earlier debts and for general corporate purposes. The company specializes in the tokenization of real-world assets, promoting its solutions in the digital asset space while highlighting potential risks associated with the offering.
Read more →STEXStreamex Corp. (NASDAQ: STEX) Acquires 9.9% Strategic Equity Stake in Royalty and Streaming Firm Empress Royalty Corp. Through a Premium Priced Share-for-Share Transaction at US$5.00 STEX with a Leading Institutional Inv
Streamex Corp. has announced the acquisition of a 9.9% equity stake in Empress Royalty Corp. through a premium-priced share-for-share transaction. The deal, valued at approximately $12.2 million, was executed at a $5.00 share price, indicating strong market demand for Streamex shares. This investment aligns with Streamex's strategy of expanding into commodities, focusing on real-world asset tokenization. Industry leaders express optimism about the partnership and its potential to bolster financial infrastructures in commodity markets.
Read more →STEXStreamex Corp. (NASDAQ: STEX) Announces Appointment of Kevin Gopaul, Global Financial Executive and ETF Pioneer to Its Board of Directors
Streamex Corp. has appointed Kevin Gopaul, a seasoned financial executive and ETF pioneer, to its Board of Directors. Gopaul brings over 25 years of experience in asset management and has a strong background in ETF product innovation. His expertise is expected to help Streamex drive growth and advance its international expansion initiatives, particularly with its flagship offering, GLDY. This appointment is seen as a pivotal step in enhancing the company's position in the digital asset market.
Read more →STEXStreamex Corp. (NASDAQ: STEX) Announces Gold Bullion Purchases & Closing of Initial USD $25,000,000 Tranche of the Previously Announced Financing; All Net Proceeds Deployed into Physical Gold Bullion USD $25,000,000 tran
Streamex Corp. (NASDAQ: STEX) has announced the closing of the first tranche of a USD $25 million financing deal dedicated to purchasing physical gold bullion, as part of their tokenization strategy. This funding will reinforce the company's gold-denominated balance sheet amidst a positive macro outlook for gold pricing. The financing indicates Streamex's commitment to integrating gold-backed assets into its product roadmap, while the remaining funds are dependent on the successful fulfillment of specific closing conditions. Overall, this transaction positions Streamex favorably within the evolving landscape of gold-backed financial instruments.
Read more →STEXStreamex Corp. (NASDAQ: STEX) Announces Nasdaq Approval for Continued Listing on Nasdaq Capital Market & Shareholder Meeting on
Streamex Corp. has received formal approval from Nasdaq for continued listing on the Nasdaq Capital Market. A special shareholder meeting is scheduled for November 4, 2025, to address the previously adjourned Acquisition Proposal. During the meeting, the executive team will present updates on the company's advancements and future strategy. This approval marks a significant milestone for Streamex, enabling them to accelerate business plans and enhance value for stakeholders.
Read more →STEXBioSig Technologies, Inc. Announces Corporate Rebrand to Streamex Corp. Strategic Rebranding to Focus on Expanded Business Model and Growth Strategy. New Ticker Symbol "STEX". LOS ANGELES & VANCOUVER, British Columbia
BioSig Technologies, Inc. has announced its corporate rebranding to Streamex Corp., which is set to take effect on September 12, 2025. The rebranding accompanies a new ticker symbol, 'STEX', as part of a strategy to expand its business model and growth initiatives. The company emphasizes its commitment to RWA tokenization in the commodities market while maintaining its medical device operations unaffected by the change. Stakeholders are reminded of potential risks, including the need for shareholder approval and compliance with Nasdaq's listing criteria.
Read more →STEXBioSig Technologies Inc. Announces Proposed Public Offering Los Angeles, CA
BioSig Technologies Inc. announced its plan to offer shares of common stock through an underwritten public offering. This move is part of the company's strategy to utilize net proceeds for purchasing gold and other corporate purposes. The offering's completion is subject to market conditions, and uncertainties exist regarding its timing and terms. The Securities and Exchange Commission has declared the shelf registration statement effective, and interested parties can access relevant documents from the SEC's website.
Read more →STEXBioSig Technologies, Inc. and Streamex Exchange Corporation Announce Definitive Agreements for up to $1,100,000,000 ($1.1B USD) in Growth Financing to Launch Gold Backed Treasury Management Strategy and to Rapidly Expand
BioSig Technologies, Inc. has entered into definitive agreements with a leading institutional investor to secure up to $1.1 billion in growth financing. This financing will support the company's ambition to become a substantial public holder of gold bullion and to implement a gold-backed treasury management strategy. Alongside its merger with Streamex Exchange Corporation, BioSig aims to utilize RWA tokenization to unlock significant market opportunities in the commodities sector. The firm expects to enhance financial flexibility and capitalize on the $142 trillion commodities market through blockchain technology.
Read more →STEXStreamex and BioSig Announce the Successful Closing of Share Exchange Transaction and Executive Leadership Changes Bringing a First-Mover Real World Asset Tokenization Company to the Nasdaq
BioSig Technologies and Streamex Exchange Corporation have completed a share exchange transaction, forming a new company dedicated to real-world asset tokenization in the commodity space. The merged entity will be led by Streamex's Co-Founder Henry McPhie, with additional leadership roles filled by members from both companies. The deal aims to unlock the potential of the US$142.851 trillion global commodity market by bringing commodities on-chain. Despite the positive outlook, the combined company faces challenges related to realizing the transaction's benefits, obtaining shareholder approval, and meeting Nasdaq's listing requirements.
Read more →STEXBioSig Technologies, Inc. Signs Definitive Share Exchange Agreement with Streamex Exchange Corp. to Launch First-Mover Real-World Asset (RWA) Tokenization Company Bringing Commodity Markets On-Chain.
BioSig Technologies, Inc. has announced a definitive share exchange agreement with Streamex Exchange Corp., aimed at creating a leader in real-world asset tokenization within the commodity market. The transaction will see Streamex become a wholly owned subsidiary, and its team will assume key roles in the combined organization. The integration intends to leverage the growing demand for tokenization solutions, aligning with BioSig's strategy to enhance shareholder value. However, the deal is subject to shareholder approval and may face various uncertainties.
Read more →STEXCONFIDENTIAL Letter of Intent
BioSig Technologies, Inc. has outlined a Letter of Intent to merge with Streamex Exchange Corporation. The transaction could allow Streamex stockholders to significantly influence BioSig's ownership structure post-merger. It is proposed that the merger will be structured as a tax-free reorganization and is subject to further due diligence, definitive agreements, and regulatory approvals. The merged entity aims to solidify its capital position with planned fundraising efforts.
Read more →STEXBioSig Regains Compliance with Nasdaq's Minimum Bid Price Requirement Los Angeles, CA
BioSig Technologies, Inc. announced it has regained compliance with Nasdaq's minimum bid price rule, as confirmed by Nasdaq on November 13, 2024. The company successfully maintained a closing bid price above $1.00 for the required duration. CEO Anthony Amato expressed enthusiasm for the company's relisting on Nasdaq and emphasized the aim to increase shareholder value. This development signifies a positive turnaround for BioSig amidst ongoing efforts to enhance its medical technology offerings.
Read more →STEXBioSig Technologies Appoints Mr. Ferdinand Groenewald to Position of Interim Chief Financial Officer and Principal Accounting Officer WESTPORT, CT
BioSig Technologies has appointed Ferdinand Groenewald as the interim Chief Financial Officer and Principal Accounting Officer. Groenewald, a certified public accountant with extensive experience in finance and accounting, is expected to play a key role in driving strategic decisions aligned with the company’s new business strategy. CEO Anthony Amato expressed optimism about Groenewald's contribution to increasing shareholder value and the company's overall growth. However, BioSig also faces various risks and uncertainties related to regulatory compliance and market conditions.
Read more →STEXBioSig Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Westport, CT
BioSig Technologies, Inc. announced a registered direct offering for 1,570,683 shares of common stock at $1.91 per share, aiming to raise approximately $3 million. Concurrently, the company will issue unregistered warrants at an exercise price of $1.78 each, expected to close by May 30, 2024, subject to customary conditions. Proceeds will go towards working capital, aligning with the company's objective to enhance operational capabilities through funding. However, the company faces challenges including compliance with Nasdaq listing requirements and the execution of cost-cutting measures.
Read more →STEXBioSig Technologies, Inc. Announces New Appointments to its Now Fully Constituted Board of Directors, which is Comprised of 5 Board Members, 3 Independent WESTPORT, CT
BioSig Technologies, Inc. has announced the appointment of five directors to its board, three of whom are independent. This newly constituted board meets compliance standards required by major U.S. Exchanges. The newly appointed members bring a wealth of experience from various sectors, particularly in medical devices, and are expected to contribute significantly to the company's strategic direction and governance.
Read more →STEXBioSig Technologies, Inc. Appoints Mr. Anthony Amato to Position of Chief Executive Officer, Effective Immediately Mr. Amato will also serve on the Company's Board of Directors WESTPORT, CT
BioSig Technologies, Inc. has appointed Mr. Anthony Amato as its new Chief Executive Officer, effective immediately. Amato, who previously led consulting efforts to address critical company issues, will also serve on the Company’s Board of Directors. The Company emphasizes its commitment to restoring and creating shareholder value through the implementation of a turnaround strategy. Challenges such as compliance with Nasdaq requirements and effective cost management remain a concern as the company moves forward.
Read more →STEXBioSig's PURE EP Platform with New Near Field Tracking Algorithm Surpasses 100 Patient Cases Company sees clinical adoption and usage of its novel Near Field Tracking algorithm, proven to reduce ablation time by approxim
BioSig Technologies, Inc. has announced that its Near Field Tracking (NFT) algorithm, part of the PURE EP Platform, has surpassed 100 completed patient cases within 90 days of its launch. Leading medical centers such as Cleveland Clinic and Mayo Clinic have adopted this innovative tool, which allows for real-time monitoring of cardiac signals, enhancing procedural efficiency during ablation procedures. The positive clinical outcomes and endorsements from electrophysiology experts suggest a promising future for the NFT algorithm in the cardiac electrophysiology market. BioSig plans to further explore expanded applications for this algorithm based on its early success.
Read more →STEXBioSig Announces Reverse Stock Split Common Stock Will Begin Trading on Split-Adjusted Basis on
BioSig Technologies, Inc. has announced a reverse stock split of its common stock at a ratio of 1-for-10, effective on February 1, 2024. This action was approved by stockholders at the annual meeting, with trading on a split-adjusted basis set to begin on February 2, 2024. The reverse stock split aims to reduce the outstanding shares from approximately 93.3 million to about 9.3 million, with adjustments made for fractional shares. BioSig continues to focus on providing advanced cardiac signal visualization technology through its PURE EP Platform.
Read more →STEXBioSig Announces Cost Reductions to Improve its Financial Standing and Shifts its Core Strategy Cost Savings Targeted to Reduce Cash Burn by 50% Core Strategy Shifts to Business Development and Distribution Partnerships
BioSig Technologies, Inc. announced cost reductions aimed at cutting annual cash burn by 50% through workforce reductions and a strategic shift towards business development and distribution partnerships. The changes come in response to increasing customer interest in their PURE EP Platform, which seeks to improve clinical support installations. While the company highlights promising clinical data regarding their platform, significant risks remain, including the challenges of maintaining morale among remaining employees and potential financial instability during the transition.
Read more →STEXLETTER TO SHAREHOLDERS December 2023 Dear fellow shareholders, As we approach the end of 2023, I want to share with you BioSig's important achievements of the past 12 months, showcase our strengths and strategies, addres
BioSig Technologies has highlighted its achievements over the past year, including a successful transition to a subscription-based model for its cardiac care platform. The company has launched upgraded software and innovative technology aimed at improving treatment for cardiac arrhythmia. Notably, major U.S. health systems have adopted their PURE EP technology. Despite facing challenges in fundraising and economic uncertainty, BioSig remains focused on driving growth and improving shareholder value in 2024.
Read more →STEXBioSig Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Westport, CT
BioSig Technologies, Inc. announced the closing of a registered direct offering of 6,996,922 shares of common stock and associated warrants, priced at $0.3573 per share. The gross proceeds from the offering are approximately $2.5 million, to be used for working capital and general corporate purposes. Wainwright & Co. acted as the exclusive placement agent for this offering, indicating market interest and support for the company's objectives.
Read more →STEXBioSig Appoints Global MedTech Leader Fred Hrkac as New Executive VP 32-year career in medical device and electrophysiology business expansion for industry bellwethers; led multiple company exits including a $1B sale in
BioSig Technologies, Inc. has appointed Fred Hrkac as the new Executive Vice President, effective November 2, 2023. Hrkac, who has over 32 years of experience in the medical device industry, previously served on BioSig's Board of Directors. His appointment is viewed positively as he is expected to leverage his extensive contacts and experience to enhance the company's operations and expand its Pure EP Platform in new markets. The leadership change reflects BioSig's commitment to growth and innovation in the electrophysiology space.
Read more →STEXSECURITIES AND EXCHANGE COMMISSION
BioSig Technologies, Inc. filed a Form 8-K report with the SEC on April 28, 2023. The report includes information on corporate presentations and summaries intended for the investment community. The documents, labeled as Exhibits 99.1 and 99.2, will be utilized at industry conferences. The filing is part of the regulatory compliance under the Securities Exchange Act of 1934.
Read more →STEXLetter to Shareholders: The year in review - what a difference 12 months make! Dear BioSig Shareholder: On behalf of BioSig Technologies, I wanted to extend a continued thank you for your ownership in the Company and for
Letter to Shareholders: The year in review - what a difference 12 months make! Dear BioSig Shareholder: On behalf of BioSig Technologies, I wanted to extend a continued thank you for your ownership in the Company and for your support. We wouldn't be here without you. Our organ
Read more →STEXBioSig Technologies, Inc. Shareholder Letter December 2017 Dear BioSig Technologies, Inc. Shareholder: As the current year draws to a close, management felt it was an appropriate time to reflect on the achievements that
BioSig Technologies, Inc. Shareholder Letter December 2017 Dear BioSig Technologies, Inc. Shareholder: As the current year draws to a close, management felt it was an appropriate time to reflect on the achievements that we have accomplished and express our new goals for the fut
Read more →STEXIP veteran Andrew Filler joins BioSig Technologies' Board of Directors Santa Monica, CA
IP veteran Andrew Filler joins BioSig Technologies' Board of Directors Santa Monica, CA, November 10, 2017 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an
Read more →STEXBioSig Technologies, Inc. Shareholder Letter April 2017 Dear BioSig Technologies, Inc. Shareholder: I am pleased to report on some of the recent developments at BioSig Technologies, Inc. (OTCQB: BSGM), most notably, the
BioSig Technologies, Inc. Shareholder Letter April 2017 Dear BioSig Technologies, Inc. Shareholder: I am pleased to report on some of the recent developments at BioSig Technologies, Inc. (OTCQB: BSGM), most notably, the collaboration with Mayo Clinic physicians. This new, expan
Read more →STEXBioSig Technologies Announces Strategic Partnership with Mayo Clinic Ten-year agreement provides know-how, intellectual property development and clinical resources to commercialize the PURE EP System and develop future t
BioSig Technologies Announces Strategic Partnership with Mayo Clinic Ten-year agreement provides know-how, intellectual property development and clinical resources to commercialize the PURE EP System and develop future technologies Minneapolis, MN, March 17, 2017-- BioSig Techn
Read more →STEXcorporate presentation 2017 Symbol: BSGM Disclaimer Symbol:BSGM * This presentation contains forward-looking statements including statements that address activities, events or developments that BioSig expects, believes o
corporate presentation 2017 Symbol: BSGM Disclaimer Symbol:BSGM * This presentation contains forward-looking statements including statements that address activities, events or developments that BioSig expects, believes or anticipates will or may occur in the future, such as pred
Read more →STEXBioSig Technologies Announces Advanced Research Program with Mayo Clinic MINNEAPOLIS, MN
BioSig Technologies Announces Advanced Research Program with Mayo Clinic MINNEAPOLIS, MN, March 23, 2016 - BioSig Technologies, Inc. (OTCQB:BSGM) today announced the establishment of an advanced research program with Dr. Samuel Asirvatham at the Mayo Clinic in Rochester, Minneso
Read more →STEXFOURTH AMENDMENT TO THE BIOSIG TECHNOLOGIES, INC. 2012 EQUITY INCENTIVE PLAN This FOURTH AMENDMENT TO THE BIOSIG TECHNOLOGIES, INC. 2012 EQUITY INCENTIVE PLAN (this " Amendment "), adopted as of
BIOSIG TECHNOLOGIES, INC. 2012 EQUITY INCENTIVE PLAN This FOURTH AMENDMENT TO THE BIOSIG TECHNOLOGIES, INC. 2012 EQUITY INCENTIVE PLAN (this "Amendment"), adopted as of May 22, 2015, subject to stockholder approval, is made and entered into by BioSig Technologies, Inc., a Delawa
Read more →STEXBioSig Appoints Patrick Gallagher to its Board of Directors Los Angeles, CA
BioSig Appoints Patrick Gallagher to its Board of Directors Los Angeles, CA - July 22, 2014 - BioSig Technologies, a company that has developed and is commercializing its proprietary, PURE EP technology platform designed to significantly improve the clinical value of cardiac rec
Read more →STEXBioSig Names Med Devices Veteran Exec Gregory D. Cash CEO, President & Director Los Angeles, CA
BioSig Names Med Devices Veteran Exec Gregory D. Cash CEO, President & Director Los Angeles, CA - July 21, 2014 - BioSig Technologies, a company that has developed and is commercializing its proprietary PURE EP technology platform designed to significantly improve the clinical v
Read more →Competitive Position
How STEX ranks across every disease it competes inCompetitive Position is a premium feature
See how STEX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial